MedTrace Logo

Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria

NCT02619929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2018-08-29

No results posted yet for this study

Summary

The aim of this non-interventional study is to assess oral vinorelbine dose schedules (initial dose, dose increase/maintenance/reduction) applied during the initial 8 weeks of treatment under routine conditions in Germany together with the underlying reasons for the respective chosen schedules.

Conditions

Interventions

DRUG

Vinorelbine oral

Sponsors & Collaborators

  • Winicker Norimed GmbH

    collaborator INDUSTRY

  • Pierre Fabre Pharma GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02619929 on ClinicalTrials.gov